[Medical and economic evaluation of donated blood screening for hepatitis C and non-A, non-B, non-C hepatitis].
The aim of this study was to evaluate the cost of hepatitis C and non-A non-B non-C screening strategy in donated blood, currently used in French transfusion centres and to assess the effect in the blood transfusion centres according to the prevalence of the disease and the intrinsec values of tests. This screening strategy was based on alanine aminotransferase assay, and HBc and HCV antibodies detection. In 1993, a survey was conducted in 26 French transfusion centers to estimate the costs of the screening strategy currently used. Average expenditure on diagnostic sets, equipment, staff and administration charges for hepatitis C and non-A non-B non-C screening were calculated. From these results, we estimated the cost of the previous strategy which did not involve HCV antibody testing, so as to determine the incremental cost between the two strategies. We used clinical decision analysis and sensitivity analysis to estimate the incremental cost-effectiveness ratio with data gathered from the literature and examine the impact on blood transfusion centre. Implemented for 100,000 volunteer blood donations, the incremental cost of the new strategy was FF 2,566,111 (1992) and the marginal effectiveness was 180 additional infected donations detected. The sensitivity analysis showed the major influence of infection prevalence in donated blood on the incremental cost-effectiveness ratio: the lower the prevalence, the higher the cost-effectiveness ratio per contaminated blood product avoided.
Vergnon
P
P
Département d'Information Médicale des Hospices Civils de Lyon, Hôtel Dieu, Lyon.
Colin
C
C
Jullien
A M
AM
Bory
E
E
Excoffier
S
S
Matillon
Y
Y
Trepo
C
C
D000328:Adult; D001771:Blood Banks; D001782:Blood Donors; D003362:Cost-Benefit Analysis; D003663:Decision Trees; D005260:Female; D005602:France; D006526:Hepatitis C / Q000517:prevention & control*; D016751:Hepatitis E / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000592:standards; D015995:Prevalence; D012680:Sensitivity and Specificity